Ouyang Ping, Jiang Xiao-yu, Yang Wen-li, Lai Wen-yan, Xu An-long
Department of Cardiology, Nanfang Hospital, First Military Medical University, Guangzhou 510515, China.
Di Yi Jun Yi Da Xue Xue Bao. 2004 Feb;24(2):158-60.
To observe the effects of recombinant Sagartia rosea cytolysin (rSrc) and Lapemis hardwickii phospholipase A2(rPLA2) on adventitial fibroblasts proliferation.
NIH-3T3 cells were cultured and treated with rSrc and rPLA2 at different concentrations for observation of cell proliferation using non-radioactive MTS/PES assay in comparison with the control group.
The ratio of cell proliferation was 0.840+/-0.061 in the control group, and was 0.263+/-0.044, 0.418+/-0.054, 0.605+/-0.063, 0.772+/-0.054 and 0.906+/-0.072 in rSrc groups corresponding to rSrc concentrations of 100, 10, 1 microg/ml and 100, 10 ng/ml respectively. rSrc was found to significantly inhibit fibroblast proliferation in a dose-dependent manner when the concentration used was above 1 microg/ml (P<0.05), as compared with the control group (P<0.05). The ratio of cell proliferation was 0.498+/-0.076, 0.937+/-0.112 and 0.978+/-0.145 in rPLA2 groups corresponding to rPLA2 concentrations of 100, 10, 1 microg/ml respectively, indicating that rPLA2 also significantly inhibited fibroblast proliferation at the concentration of 100 microg/ml (P<0.05).
rSrc and rPLA2 can both significantly inhibit adventitial fibroblast proliferation.